CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback